See more : Amgen Inc. (AMG.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Arcellx, Inc. (ACLX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arcellx, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Verano Holdings Corp. (VRNO.CN) Income Statement Analysis – Financial Results
- Odawara Engineering Co., Ltd. (6149.T) Income Statement Analysis – Financial Results
- Scottie Resources Corp. (SCTSF) Income Statement Analysis – Financial Results
- MLP SE (MLP.DE) Income Statement Analysis – Financial Results
- Parallax Health Sciences, Inc. (PRLX) Income Statement Analysis – Financial Results
Arcellx, Inc. (ACLX)
About Arcellx, Inc.
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 110.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 2.22M | 1.04M | 629.00K | 326.00K | 0.00 |
| Gross Profit | 110.32M | -2.22M | -1.04M | -629.00K | -326.00K | 0.00 |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 133.85M | 149.56M | 46.88M | 25.06M | 15.77M | 6.11M |
| General & Administrative | 66.35M | 41.70M | 18.14M | 7.04M | 2.21M | 2.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 66.35M | 41.70M | 18.14M | 7.04M | 2.21M | 2.20M |
| Other Expenses | 0.00 | 0.00 | 49.00K | 1.00K | 2.00K | 0.00 |
| Operating Expenses | 200.20M | 191.26M | 65.02M | 32.10M | 17.97M | 8.31M |
| Cost & Expenses | 200.20M | 191.26M | 65.02M | 32.10M | 17.97M | 8.31M |
| Interest Income | 23.70M | 4.30M | 300.00K | 1.00K | 0.00 | 0.00 |
| Interest Expense | 3.84M | 1.72M | 10.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.04M | 2.22M | 1.04M | 629.00K | 326.00K | 93.00K |
| EBITDA | -64.15M | -184.74M | -63.93M | -31.47M | -17.65M | -8.22M |
| EBITDA Ratio | -58.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -89.88M | -191.26M | -65.02M | -32.10M | -17.97M | -8.31M |
| Operating Income Ratio | -81.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 19.85M | 2.58M | 49.00K | 1.00K | 2.00K | 999.00 |
| Income Before Tax | -70.03M | -188.68M | -64.97M | -32.10M | -17.97M | -8.31M |
| Income Before Tax Ratio | -63.48% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 663.00K | -2.58M | -1.04M | 422.70K | 154.14K | 0.00 |
| Net Income | -70.69M | -186.10M | -63.93M | -32.10M | -17.97M | -8.31M |
| Net Income Ratio | -64.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.47 | -4.22 | -1.79 | -0.96 | -0.52 | -50.17 |
| EPS Diluted | -1.47 | -4.22 | -1.79 | -0.96 | -0.52 | -50.17 |
| Weighted Avg Shares Out | 48.06M | 44.11M | 35.74M | 33.54M | 34.78M | 165.58K |
| Weighted Avg Shares Out (Dil) | 48.06M | 44.11M | 35.74M | 33.54M | 34.78M | 165.58K |
Arcellx Announces Participation at the Barclays Global Healthcare Conference
U.S. IPO Weekly Recap: The February IPO Market Kicks Off With 2 Biotechs
CAR-T Player Arcellx Raises $123M Via Initial Public Offering, Opens Trading At $19
Arcellx sets IPO terms, looks to raise up to $140.3 million
Source: https://incomestatements.info
Category: Stock Reports